Rathbones Group PLC Has $263.13 Million Stock Holdings in Boston Scientific Corporation $BSX

Rathbones Group PLC raised its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 20.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,759,657 shares of the medical equipment provider’s stock after purchasing an additional 477,680 shares during the period. Boston Scientific accounts for 1.0% of Rathbones Group PLC’s portfolio, making the stock its 23rd largest holding. Rathbones Group PLC’s holdings in Boston Scientific were worth $263,133,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BSX. Egerton Capital UK LLP grew its holdings in Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after purchasing an additional 3,671,548 shares during the last quarter. Jennison Associates LLC grew its holdings in Boston Scientific by 133.5% during the third quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after purchasing an additional 2,823,744 shares during the last quarter. Alphinity Investment Management Pty Ltd acquired a new position in Boston Scientific during the fourth quarter valued at approximately $252,918,000. Marshall Wace LLP grew its holdings in Boston Scientific by 30.7% during the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock valued at $956,680,000 after purchasing an additional 2,301,383 shares during the last quarter. Finally, Credit Agricole S A acquired a new position in Boston Scientific during the third quarter valued at approximately $204,812,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Oppenheimer set a $90.00 price target on Boston Scientific in a report on Thursday, April 23rd. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Sanford C. Bernstein reiterated an “outperform” rating and set a $112.00 price target on shares of Boston Scientific in a report on Friday, February 6th. Stifel Nicolaus reduced their price objective on Boston Scientific from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. Finally, Barclays reduced their price objective on Boston Scientific from $124.00 to $96.00 and set an “overweight” rating for the company in a research report on Thursday, April 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $92.71.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported positive pivotal results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter in the FRACTURE trial, meeting key safety and effectiveness endpoints in patients with severely calcified coronary artery disease. The company plans to use the data to support a regulatory filing, which strengthens its cardiovascular pipeline and could expand future revenue. Article Title
• Positive Sentiment: The company announced a $2 billion accelerated share repurchase and a broader $5 billion buyback authorization, signaling confidence in its valuation and providing support for earnings per share over time. Article Title
• Positive Sentiment: Boston Scientific also invested $1.5 billion for an equity stake in MiRus, with an option tied to the company’s TAVR business, which could deepen BSX’s position in structural heart and create an additional growth path. Article Title
• Neutral Sentiment: Baird lowered its price target on BSX to $75 from $78 but kept an Outperform rating, suggesting analysts remain constructive even after revising near-term expectations lower. Article Title
• Neutral Sentiment: Other recent broker updates were mixed, with some firms reaffirming Buy ratings while Bank of America also trimmed its target, keeping the analyst backdrop supportive but not especially strong. Article Title
• Negative Sentiment: Some market commentary and fund commentary referenced BSX as having “weak results” or falling on that basis, which adds to the perception of recent pressure on the shares. Article Title

Boston Scientific Stock Down 0.4%

BSX opened at $56.59 on Thursday. Boston Scientific Corporation has a 1-year low of $52.52 and a 1-year high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $84.11 billion, a price-to-earnings ratio of 23.68, a P/E/G ratio of 1.04 and a beta of 0.62. The business has a 50 day moving average of $62.46 and a 200-day moving average of $80.71.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the prior year, the business earned $0.75 earnings per share. Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has approved a stock repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.